Castration-resistant prostate cancer: Targeted therapies

Chemotherapy

Volumn 57, Issue 2, 2011, Pages 115-127

  Leo, S ^a   Accettura, C ^a   Lorusso, V ^a  

^a VITO FAZZI HOSPITAL   (Italy)

Author keywords

Castration resistant prostate cancer; Elderly men; Targeted therapy

Indexed keywords

AFLIBERCEPT; AROMATASE INHIBITOR; ATRASENTAN; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CIXUTUMUMAB; DASATINIB; DENOSUMAB; DEXAMETHASONE; DOCETAXEL; ERLOTINIB; ESTRAMUSTINE; FIGITUMUMAB; GEFITINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; LOW MOLECULAR WEIGHT HEPARIN; MITOXANTRONE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN TYROSINE KINASE; PROVENGE; SARACATINIB; SORAFENIB; SUNITINIB; THALIDOMIDE; UNINDEXED DRUG; ZIBOTENTAN; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ADVANCED CANCER; ALKALINE PHOSPHATASE BLOOD LEVEL; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE DENSITY; BONE METABOLISM; BONE METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER REGISTRY; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL SKIN REACTION; CLINICAL TRIAL (TOPIC); COMPETITIVE INHIBITION; CONSTIPATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HORMONE RESISTANT PROSTATE CANCER; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; KIDNEY CANCER; LIVER FUNCTION TEST; MAXIMUM TOLERATED DOSE; MEDLINE; METASTASIS; MOLECULAR DYNAMICS; MONOTHERAPY; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN TARGETING; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STEROIDOGENESIS; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MALE; MOLECULAR TARGETED THERAPY; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 79952845566     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000323581     Document Type: Review

References (74)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics. CA Cancer J Clin 2008; 58: 71-96.
2. Shibata A, Whittemore AS: Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst 2001; 93: 1109-1111.
3. Balducci L, Beghe C: Cancer and age in the USA. Crit Rev Oncol Hematol 2001; 37: 137-145. (Pubitemid 32106913)
4. Kanthoff PW, Halabi S, Conaway M, et al: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of Cancer and Leukemia Group B 9182 Study. J Clin Oncol 1999; 17: 2506-2513. (Pubitemid 29368252)
5. Tannock IF, Osoba D, Stockler MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomised trial with palliative end points. J Clin Oncol 1996; 14: 1756-1764. (Pubitemid 26185452)
6. Petrylak D, Tangen CM, Hussian MH, et al: SWOG 99-16: docetaxel and extramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520. (Pubitemid 39315318)
7. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512. (Pubitemid 39315317)
8. Berthold DR, Pond GR, Soban F, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242-245.
9. Armstrong AJ, George DJ: New drug development in metastatic prostate cancer. Urol Oncol 2008; 26: 430-437. (Pubitemid 351888378)
10. Shah RB, Mehra R, Chinniyan AM, et al: Androgen- independent prostate cancer is an heterogeneous group of diseases: lesson from a rapid autopsy program. Cancer Res 2004; 64: 9209-9216. (Pubitemid 39665537)
11. Jimenez JA, Kao C, Raikwar S, et al: Current status of antiangiogenic therapy for prostate cancer. Urol Oncol 2006; 24: 260-268.
12. George DJ, Halabi S, Shepard TF, et al: Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001; 7: 1932-1936. (Pubitemid 32994827)
13. Reese DM, Fratesi P, Corry M, et al: A phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer. Prostate 2001; 3: 65-70. (Pubitemid 34169203)
14. Kelly WK, Halabi S, Carducci MA, et al: A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401 (abstract). J Clin Oncol 2010; 28(suppl):18s.
15. Di LG, Figg WD, Fossa SD, et al: Combination of bevacizumab and docetaxel in docetaxel pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 2008; 54: 1089-1094.
16. Lau SC, Rosa DD, Jaison G: Technology evaluaation: VEGF Trap (cancer), Regeneron/ Sanofi-Aventis. Curr Opin Mol Ther 2005; 7: 493-501. (Pubitemid 41489191)
17. National Institutes of Health: Anfibercept in combination with docetaxel in metastatic androgen independent prostate cancer (VENICE). 2010. http://clinicaltrials.gov/ ct2/show/NCT00519285.
18. Verheul HM, HammersH, van Herp K, et al: Vascular endothelial growth factor blocks tumor growth, metastasis formation, and vascular leakage in orthotopic murine renal cancer model. Clin Cancer Res 2007; 13: 4201-4208. (Pubitemid 47105984)
19. D'Amato RJ, Loughnan MS, Flynn E, et al: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-4088.
20. Figg WD, Kruger EA, Price DK, et al: Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Invest News Drugs 2002; 20: 183-194. (Pubitemid 34632653)
21. Drake MJ, Robson W, Mehta P, et al: An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer 2003; 88: 822-827. (Pubitemid 36520866)
22. Dahut WL, Gulley JL, Arlen PM, et al: Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004; 22: 2532-2539. (Pubitemid 41103740)
23. Figg WD, Raje S, Bauer KS, et al: Pharmacokinetics of thalidomide in an elderly prostate cancer population. J Pharm Sci 1999; 88: 121-125. (Pubitemid 29037378)
24. Dahut WL, Scripture C, Posadas E, et al: A phase II clinical trial of sorafenib in androgen- independent prostate cancer. Clin Cancer Res 2008; 14: 209-214. (Pubitemid 351377997)
25. Aragon-Ching JB, Jain L, Gully JL, et al: Final analysis of phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int 2009; 103: 1636-1640.
26. National Institutes of Health: Sorafenib to overcome resistance to systemic chemotherapy in androgen-independent prostate cancer. 2010. http://www.clinicaltrials.gov/show/ NCT00414388.
27. Scher HI, Halabi S, Tannock I, et al: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-1159.
28. Sonpavde PO, Periman D, Bernold D, et al: Sunitinib malate for metastatic castrationresistant prostate cancer following docetaxel- based chemotherapy. Ann Oncol 2010; 21: 319-324.
29. Zurita J, Liu G, Hutson T, et al: Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refractory prostate cancer (abstract). J Clin Oncol 2009; 27: 15s.
30. Dror M, Michaelson MM, Regan WK, et al: Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009; 20: 913-920.
31. Aragon-Ching B, Dahut WL: About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here? Ann Oncol 2010; 21: 183-184.
32. Gravis G, Bladou F, Salem N, et al: Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Ann Oncol 2008; 19: 1624-1628.
33. Gross M, Higano C, Pantuck A, et al: A phase II trial of docetaxel and erlotinib as first line therapy for elderly patients with androgenindependent prostate cancer. BMC Cancer 2007; 7: 142.
34. Canil CM, Moore MJ, Winquist E, et al: Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2005; 23: 455-460. (Pubitemid 46224221)
35. Boccardo F, Rubagotti A, Conti G, et al: Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormonerefractory prostate cancer: a randomized phase II trial. Oncology 2008; 74: 223-228.
36. Tatarov O, Mitchell TJ, Seywright M, et al: Src family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res 2009; 15: 3540-3549.
37. Fizazi K: The role of Src in prostate cancer. Ann Oncol 2007; 18: 1765-1773. (Pubitemid 350119560)
38. Yu EY, Wilding G, Posadas E, et al: Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009; 15:7421-7428.
39. Araujo J, Gallick G, Trudel G, et al: Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer a phase I/II study (CA180- 086) (abstract). J Clin Oncol 2009; 27: 15s.
40. National Institutes of Health: A randomized double-blind phase III trial comparing docetaxel combined with dasatinib to docetaxel combined to placebo in castrationresistant prostate cancer. http://clinicaltrials. gov/ct2/show/ NCT0074497.
41. Lara PN Jr, Longmate J, Evans CP, et al: A phase II trial of Src-kinase inhibitor AZD0530 in patients with advanced castration resistant prostate cancer: a California Cancer Consortium study. Anticancer Drug 2009; 20: 179-184.
42. Sabbatini P, Larson SM, Kremer A, et al: The prognostic significance of extent of disease in bone in patients with androgen independent prostate cancer. J Clin Oncol 1999; 17: 948-957. (Pubitemid 29109328)
43. Nelson JB, Hedican SP, George DJ, et al: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995; 1: 944-949.
44. Nelson J, Bagnato A, Battistini B: The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003; 3: 110-116. (Pubitemid 37328878)
45. Carducci MA, Jimeno A: Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 2006; 12: 6296-6300.
46. Nelson JB, Love W, Chin JL, et al: Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic hormone-refractory prostate cancer. Cancer 2008; 113: 2478-2487.
47. Carducci MA, Saad F, Abrahamsson PA, et al: A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007; 110: 1959-1966. (Pubitemid 350036854)
48. Armstrong AJ, Creel P, Turnbull J: A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2008; 14: 6270-6276.
49. National Institutes of Health: Docetaxel and prednisone with or without atrasentan in treating patients with stage IV prostate cancer and bone metastases that did not respond to previous hormone therapy (identifier NCT00134056). 2010. http://www.clinicaltrials. gov.
50. James ND, Borre M, Zonnenberg B, et al: ZD4054, a potent, specific endothelin A receptor antagonist, improves overall survival in pain-free or mildly symptomatic patients with hormone-resistant prostate cancer and bone metastases (abstract). Eur J Cancer 2007; 5(suppl):3.
51. National Institutes of Health: A phase III trial of ZD4054 (zibotentan) (endothelin A antagonist) and docetaxel in metastatic hormone- resistant prostate cancer. 2010. http:// clinicaltrials.gov/ct2/show/NCT00617669.
52. Chen G, Sircar K, Aprikian A, et al: Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 2006; 107: 289-298. (Pubitemid 44036558)
53. Ellis GK, Bone HG, Chlebowski R, et al: Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008; 26: 4875-4882.
54. Bone HG, Bolognese MA, Yuen CK, et al: Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008; 93: 2149-2157. (Pubitemid 351831529)
55. Bamias A, Kastritis E, Bamia C, et al: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23: 8580-8587. (Pubitemid 46211499)
56. Fizazi K, Carducci A, Smith MR, et al: A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer (abstract). J Clin Oncol 2010; 28(suppl): 18s.
57. Getzenberg RH, Light BW, Lapco PE, et al: Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 1997; 50: 999-1006. (Pubitemid 28021128)
58. Beer TM, Eilers KM, Garzotto M, et al: Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003; 21: 123-128.
59. Beer TM, Ryan CV, Venner PM, et al: Double- blinded randomized study of high-dose calcitriol plus docetaxel in androgen-independent prostate cancer: a report from ASCENT Investigators. J Clin Oncol 2007; 25: 669-674. (Pubitemid 350002922)
60. Scher HI, Chi KN, De Wit R, et al: Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): results from the phase III ASCENT2 trial (abstract). J Clin Oncol 2010; 28: 4509.
61. Samani AA, Yakar S, Le Roith D, et al: The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007; 28: 20-47. (Pubitemid 46220849)
62. Kurmasheva RT, Houghton PJ: IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta 2006; 1766: 1-22. (Pubitemid 44175635)
63. Krueckl SL, Sikes RA, Edlund NM, et al: Increased insulin-like growth factor I receptor expression and signalling are components of androgen-independent progression in a lineage- derived prostate cancer progression model. Cancer Res 2004; 64: 8620-8629. (Pubitemid 39552075)
64. Renehan AG, Zwahlen M, Minder C, et al: Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004; 363: 1346-1353. (Pubitemid 38529873)
65. Chan JM, Stampfer MJ, Ma J, et al: Insulinlike growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002; 94: 1099-1106. (Pubitemid 34830730)
66. Hellawell GO, Turner GD, Davies DR, et al: Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002; 62: 294250.
67. Krueckl SL, Sikes RA, Edlund NM, et al: Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage- derived prostate cancer progression model. Cancer Res 2004; 64: 8620-8629. (Pubitemid 39552075)
68. Wu JD, Odman A, Higgins LM, et al: In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 2005; 11: 3065-3074. (Pubitemid 40525213)
69. National Institutes of Health: A phase 2, randomized, non-comparative, two arm open label, multiple-center study of CP-751871 in combination with docetaxel/prednisone in chemotherapy naive (arm a) and docetaxel/ prednisone refractory (arm b) patients with hormone insensitive prostate cancer. http:// clinicaltrials.gov/ct2/show/NCT00313781.
70. National Institutes of Health: Phase 2 singlearm, open-label study of IMC-A12 in asymptomatic, chemotherapy-naïve patients with metastatic androgen independent prostate cancer. 2010. http://clinicaltrials.gov/ct2/ show/NCT00520481.
71. Fizazi K, Sternberg CN, Fitzpatrick JM, et al: Role of targeted therapy in the treatment of advanced prostate cancer. BJU Int 2010; 105: 748-767.
72. Danila D, Hellen G, Gignac GA, et al: Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007; 13: 7053-7058. (Pubitemid 350276887)
73. Vainas GI: Octreotide in the management of hormone-refractory prostate cancer. Chemotherapy 2001; 47: 109-126.
74. Jerkins SA, Kynaston HG, Davies N: Somatostatin analogs in oncology: a look to the future. Chemotherapy 2001; 47: 162-196.